Bristol Myers Squibb has signed a significant $380 million agreement with Cellares to enhance the production and supply of CAR-T cell therapies. This partnership aims to extend the reach of these therapies to more patients across the United States, European Union, and Japan. The deal involves Cellares acting as a contract manufacturer to help meet the growing demand for these innovative treatments.
Bristol Myers taps startup to boost CAR-T production https://t.co/veatQq5IdF $BMY by @NedPagliarulo
Bristol Myers taps startup to boost CAR-T production https://t.co/TbDi6P9735 by @NedPagliarulo $BMY $NVS $GILD
Buy this little-known pharma stock with more than 80% upside ahead, RBC says https://t.co/08kEz8jRy1
$JNJ / $LEGN Carvykti joins Abecma in EU expansion, just as $BMY announces a new manufacturing deal. Will this help BCMA Car-T sales pick up? Quick take via @ApexOnco https://t.co/kK8TC1l6a5
Drugmaker Bristol Myers Squibb said it has signed a $380 million deal with contract manufacturer Cellares to manufacture its CAR-T cell therapies in the United States, EU and Japan. https://t.co/duVAnO6NoG https://t.co/duVAnO6NoG
Bristol Myers signs $380 mln CAR-T therapies supply deal with Cellares https://t.co/Tv7pvkA8Q2 https://t.co/rGll62Y6LE
Bristol Myers Squibb and Cellares said on Monday they have reached a $380 million deal to supply CAR-T cell therapies to more patients. https://t.co/hutUZO9GAQ https://t.co/hutUZO9GAQ
⚠️ BRISTOL MYERS SQUIBB AND CELLARES REACH $380 MILLION SUPPLY DEAL FOR CAR-T THERAPIES Full Story → https://t.co/NJmioIlBmE Bristol Myers Squibb and Cellares said on Monday they have reached a $380 million deal to supply CAR-T cell therapies to more patients. https://t.co/puSQfKEWF4